NMT Medical (Boston) in late January said it was closing its PFO/migraine trial, MIST II, citing "challenges" in patient enrollment.
Browse by Speciality Area
Browse by Speciality Area
All Access Subscription
Get unlimited access to our full publication and article library.
Get Access NowInterested in Group Sales? Learn more